Contact Us

Breast Cancer
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

If you believe breast cancer developed as the result of a drug (i.e. Prempro), please list drug:

Date you started taking this drug:

Date you stopped taking this drug:

If diagnosed with breast cancer, please indicate details of diagnosis:



Have any family members (sisters, mother, grandmothers) been diagnosed with breast cancer?

If yes, please describe which family member was diagnosed and the type of cancer that was diagnosed:

Have you been genetically screened for breast cancer?

If you have been screened for breast cancer, please describe results:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Breast Cancer Risk May Rise with Recent Depo-Provera Use

Apr 5, 2012 | Parker Waichman LLP

Depo-Provera an Injectable Contraceptive Used by 1.2 million U.S. Women

Depo-Provera (depo-medroxyprogesterone acetate, or DMPA) an injectable contraceptive used by about 1.2 million U.S. women, may increase the risk of invasive breast cancer in young women.  Depo-Provera is a progestin-only birth control method, and is made with the same type of progestin found in Prempro, a hormone replacement therapy medication that has been associated with breast cancer in post-menopausal women. 

Few studies have been done to assess the potential of Depo-Provera to cause breast cancer in young women.  However, some international studies have produced mixed findings.  To add to knowledge about this possible risk, researchers at the Fred Hutchinson Cancer Center compared data on 1,028 Seattle-area women ages 20 to 44 who had been diagnosed with breast cancer to 919 age-matched controls who did not have a history of breast cancer. About 10 percent of subjects in the study reported using Depo-Provera.

Depo-Provera Associated 2.2-fold Increased Risk of Invasive Breast Cancer

Recent use of Depo-Provera (within five years) for 12 months or longer was associated with a 2.2-fold increased risk of invasive breast cancer, the study found. Women who used DMPA for less than a year or who had stopped using it more than a year earlier did not have an increased risk of breast cancer.  The risk began to lessen in the months after a woman stopped using Depo-Provera.

“While DMPA is widely used by women throughout the world, there are limited data on the association between DMPA and breast cancer incidence,” Christopher I. Li, M.D., PhD., a member of the Hutchinson Center’s Public Health Sciences Division, said in a press release. “Our study adds to the body of knowledge from international studies conducted in a diverse group of countries – Kenya, New Zealand, Thailand, Mexico and Costa Rica – which have shown that one of the risks associated with DMPA use may be an increased risk of breast cancer."

Need Legal Help Regarding Breast Cancer Risk With Recent Depo-Provera Use

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).


Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo